Overview

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the safety, tolerability, and effectiveness of darunavir/ritonavir combined with TMC125 when current protease inhibitor(s), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI(s)) and enfuvirtide are replaced by darunavir/ritonavir and TMC125 in HIV positive patients who can no longer tolerate enfuvirtide and are experiencing viral suppression. Other antiviral drugs in the regimen are to remain unchanged.

Phase:

Phase 3

Details

Lead Sponsor:

Tibotec, Inc

Collaborator:

Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Treatments:

Darunavir
Enfuvirtide
Etravirine
HIV Protease Inhibitors
Protease Inhibitors
Ritonavir